查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553702

阿霉素市场规模、份额、趋势分析报告：按剂型、按应用、按分销管道、按地区、细分市场预测，2024-2030

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格
简介目录

阿霉素市场成长和趋势：

Grand View Research最新报告显示，到2030年，全球阿霉素市场规模预计将达到15.3亿美元，预测期内复合年增长率为6.6%。

越来越多的参与者进入市场以遏制药物短缺，这是预计未来几年推动市场的关键因素之一。阿霉素的製造商包括 Ortho Biotech Products, LP、Ben Venue Laboratories, Inc. 和 Bristol-Myers Squibb Company。对阿霉素的需求是由其在各种应用中不断增加的适应症所推动的，包括爱滋病相关的卡波西氏肉瘤、多发性骨髓瘤、神经母细胞瘤、骨癌和卵巢癌。克服不良健康影响的药物配方技术进步以及奈米颗粒和脂质体涂层等各种类型的药物传输系统的引入是推动该行业成长的一些关键因素。

美国政府发布行政命令，解决美国救生药物、化疗药物和急需药物的短缺问题。根据监测、流行病学和最终结果 (SEER) 估计，2016 年恶性患者的预期数量为：-

  • 白血病 60,140 人
  • 乳癌 2,46,660 人
  • 60,050 人患有子宫内膜癌
  • 胃癌 26,370 人
  • 肝癌：39,230 人
  • 肾癌：62,700 人

根据白血病和淋巴瘤协会2016年的估计，预计约有60,140人被诊断出患有白血病。盛行率的增加和随后生存率的增加是技术进步和新治疗方法越来越多采用的因素之一。

阿霉素市场报告亮点

  • 2023年，阿霉素市场最大的应用将是乳癌。该药物与Cisplatin联合治疗的需求不断增长是预计推动阿霉素市场的关键因素之一。
  • 在预测期内，膀胱癌领域预计将以显着的复合年增长率成长。阿霉素是晚期膀胱癌的标准治疗方法，仍然是该疾病治疗的重要组成部分。
  • 2023年，北美占据全球阿霉素市场的大部分，市场占有率超过37.7%。强生公司和太阳製药工业有限公司等强大市场参与者的存在以及对有效药物替代品的认识不断提高是该地区高市场占有率的主要因素。
  • 亚太地区是该市场成长最快的地区。中国、日本和印度等国家抗癌药物治疗需求未满足以及製药业快速成长是预计未来几年推动市场发展的因素之一。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章阿霉素市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 阿霉素市场分析工具
    • 波特的分析
    • PESTEL分析

第四章阿霉素市场：按剂型的估计和趋势分析

  • 细分仪表板
  • 阿霉素市场：2023 年和 2030 年剂型变化分析
  • 冻干粉
  • 阿霉素注射液

第五章阿霉素市场：按应用估计和趋势分析

  • 细分仪表板
  • 阿霉素市场：应用分析，2023 年和 2030 年
  • 膀胱癌
  • 卡波西氏肉瘤
  • 白血病
  • 淋巴瘤
  • 其他的

第六章阿霉素市场：按分销管道估算和趋势分析

  • 细分仪表板
  • 阿霉素市场：2023 年和 2030 年分销通路变化分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章阿霉素市场：区域估计和趋势分析

  • 2023 年及 2030 年阿霉素市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sun Pharmaceutical Industries Ltd
    • Cipla.
    • Cadila Pharmaceuticals.
    • Novartis AG
    • Dr. Reddy's Laboratories Ltd.
    • SRS Life Sciences
    • MicroBiopharm Japan Co., Ltd.
    • Baxter
简介目录
Product Code: GVR-1-68038-288-4

Doxorubicin Market Growth & Trends:

The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

  • Leukemia 60,140
  • Breast cancer 2,46,660
  • Endometrial cancer 60,050
  • Gastric cancer 26,370
  • Liver cancer 39,230
  • Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Doxorubicin Market Report Highlights:

  • In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
  • Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.
  • In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
  • Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Doxorubicin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Doxorubicin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Doxorubicin Market: Drug Formulation Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Doxorubicin Market: Drug Formulation Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Lyophilized Powder
    • 4.3.1. Lyophilized Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Doxorubicin Injection
    • 4.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Doxorubicin Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Doxorubicin Market: Application Analysis, 2023 & 2030 (USD Million)
  • 5.3. Bladder Cancer
    • 5.3.1. Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Kaposi Sarcoma
    • 5.4.1. Kaposi Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Leukemia
    • 5.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Lymphoma
    • 5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Doxorubicin Market: Regional Estimates & Trend Analysis

  • 7.1. Doxorubicin Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific
    • 7.4.2. Asia Pacific Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. India
      • 7.4.5.1. India Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Australia
      • 7.4.7.1. Australia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Thailand
      • 7.4.8.1. Thailand Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sun Pharmaceutical Industries Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Cipla.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Cadila Pharmaceuticals.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Dr. Reddy's Laboratories Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. SRS Life Sciences
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. MicroBiopharm Japan Co., Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Baxter
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives